Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CROSSBOW: 131I-PSMA-1095 in Metastatic Prostate Cancer
NCT04085991Phase 2Terminated
- Sponsor
- Jewish General Hospital
- Start
- Jul 2020
- Primary completion
- Jan 2023
- Countries
- 1
01
Overview
A Phase 2 trial of mip-1095 i-131 in prostate cancer (PCa), sponsored by Jewish General Hospital. Started Jul 2020; status: terminated.
02
Drugs
mip-1095 i-131
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04085991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04085991.